Latest Earnings Results: Q2 '26
Estimated EPS
$0.26
Reported EPS
$0.28
Surprise
+5.66%
Estimated Rev
$81.79M
Reported Rev
$83.22M
Surprise
+1.75%
• Reported GAAP EPS of $0.29 up 81.25% YoY • Reported revenue of $58.57M down -16.33% YoY • Aurinia Pharmaceuticals Inc. reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and net product sales of $305 million to $315 million.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.22 | -- | -- | N/A |
Q2 '26 | $0.26 | $0.28 | 5.66% | BEAT |
Q1 '26 | $0.19 | $0.25 | 28.21% | BEAT |
Q4 '25 | $0.22 | $1.53 | 606.15% | BEAT |
Q3 '25 | $0.16 | $0.23 | 43.75% | BEAT |